Warning co-cyprindiol-FSRH

Question 1

What is Co-cyprindiol recommendations of EMA + MHRA and FSRH.

Answer 1

• Cyproterone acetate 2mg / EE 35 mcg.
• European Medicines Agency (EMA) and Medicines & Healthcare products Regulatory Authority ( MHRA) a letter issued to raise awareness of thrombosis risks.
• FSRH : thrombosis risks still can be used for contraception but should not be used solely for this purpose.

Question 2

Woman to tell patient at time of prescribing co-cyprindiol.

Answer 2

• increase risk of VTE than nonusers or LNG users.
• Absolute risk low.
• less than risk in pregnancy.
• used appropriately , benefits of CHC & co- cyprindiol outweighs risk of VTE particularly when used for non contraceptive benefits.
• guided by UKMEC